Sugi Predict

Sugi Predict / Compounds / SCHEMBL2472365

SCHEMBL2472365

SCHEMBL2472365

Cc1[nH]c2c(N(Cc3ccccc3)Cc3ccccc3)nc(Cl)cc2c1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ MAT2A P31153 1/20 0.39
▸ CYP2C19 P33261 2/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ MAPT P10636 4/20 0.36
▸ LMNA P02545 3/20 0.36
▸ HIF1A Q16665 1/20 0.36
▸ GAA P10253 2/20 0.35
▸ NPSR1 Q6W5P4 2/20 0.35
▸ TP53 P04637 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ XBP1 P17861 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ ATM Q13315 1/20 0.35
▸ NR3C1 P04150 3/20 0.35
▸ PIM1 P11309 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2476450 0.83 FABP4 (0.46) CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL2473061 0.83 ALDH1A1 (0.41) MAT2ACYP2C19CYP1A2CYP3A4CYP2D6
SCHEMBL2473785 0.81 KDM4E (0.38) SMN1; SMN2CYP2C19CYP1A2CYP3A4CYP2D6
SCHEMBL2475750 0.78 SMN1; SMN2 (0.41) SMN1; SMN2MAT2ACYP2C19MAPTLMNA
SCHEMBL1736959 0.76 CSF1R (0.40) SMN1; SMN2MAT2AMAPTPIM1ALDH1A1
SCHEMBL2474375 0.75 CYP3A4 (0.55) CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL2479027 0.73 MAPT (0.43) SMN1; SMN2MAPTLMNATP53TSHR
SCHEMBL2477220 0.72 SMN1; SMN2 (0.38) SMN1; SMN2MAPTLMNAGAANPSR1
SCHEMBL5568738 0.72 PDE4A (0.38) SMN1; SMN2MAT2ACYP2C19MAPTLMNA
SCHEMBL2479067 0.69 CSF1R (0.46) SMN1; SMN2MAT2ACYP2C19CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1787991-B2 PYRROLO[2,3-c]PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE TAKEDA PHARMACEUTICALS CO (JP) 2020-06-24 — — EP disclosed
US-20180148446-A1 PYRROLO [2,3-c] PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE TAKEDA PHARMACEUTICALS CO (JP) 2018-05-31 — — US disclosed
EP-1787991-B1 PYRROLO[2,3-c]PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE TAKEDA PHARMACEUTICAL (JP) 2011-10-05 — — EP disclosed
US-20070293532-A1 Pyrrolo [2,3-C] Pyridine Compound, Process for Producing the Same, and Use TAKEDA PHARMACEUTICAL COMPAN6Y LIMITED (JP) 2007-12-20 — — US disclosed
EP-1787991-A1 PYRROLOÝ2,3-c¨PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Pharmaceutical Company Limited (JP) 2007-05-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148446-A1 PYRROLO [2,3-c] PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE PGA5, ATP6AP1, PPA1 SMN1; SMN2 3534/4885MAT2A 1795/4885CYP2C19 99/4885
US-20070293532-A1 Pyrrolo [2,3-C] Pyridine Compound, Process for Producing the Same, and Use PGA5, ATP6AP1, PPA1 SMN1; SMN2 3534/4885MAT2A 1795/4885CYP2C19 99/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.